Alterity's US-listed shares rise as new study begins in rare Parkinsonian disorder drug

Alterity Therapeutics

30/05/2023 18:18

** U.S.-listed shares of Australia-based drug developer
Alterity Therapeutics Ltd  ATHE.O   ATH.AX  rise 9.4% to $2.85
    ** Co commences a new mid-stage trial of its lead drug,
ATH434, in patients with multiple system atrophy (MSA); says
first patient enrolled
    ** This is in addition to another mid-stage study in
early-stage MSA - co
    ** MSA is a rare condition of the nervous system that causes
gradual damage to nerve cells in the brain
    ** The new trial will enroll approximately 15 individuals
with more advanced MSA; co expects to generate data before
ongoing mid-stage trial 
    ** U.S.-listed stock down ~18% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))